Viscera Labs

Executive Summary

Viscera Labs is a private biopharmaceutical company founded in 2018 and based in San Francisco, focused on developing cost-effective therapeutics for bile acid-mediated disorders, including metabolic and liver diseases. The company leverages a leadership team with deep expertise in gastroenterology and drug development to address significant unmet medical needs. While still in early stages, Viscera Labs targets a niche area with high unmet need, positioning it for potential growth. However, limited public information on pipeline, funding, and clinical progress introduces uncertainty. The company faces typical early-stage risks, including clinical trial failures and capital requirements, but its specialized focus could attract strategic partnerships. Overall, Viscera Labs represents a speculative opportunity within the metabolic and liver disease space, with potential upside if its lead candidates advance successfully.

Upcoming Catalysts (preview)

• Q3 2026IND Filing or Phase 1 Initiation for Lead Candidate60% success
• Q4 2026Presentation of Preclinical Proof-of-Concept Data70% success
• TBDAnnouncement of Strategic Partnership or Licensing Deal30% success